Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:12:43.634Z.
Calculation as of: 2026-10-06T15:12:43.634Z.
Quote observation: 2026-10-06T15:10:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 764f42141b21779aba3712b54ee9373bee46ed3fd4a49ef41b5b57d04fae8ed9
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $246.29M | N/A | N/A | N/A | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $245.86M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.82M | N/A | 2.31 | 2.31 | 2.31 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $241.60M | N/A | N/A | N/A | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $249.31M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $242.56M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $240.82M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $240.71M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $238.13M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.01M | N/A | 1.36 | 0.90 | 0.77 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
